Article
TP-0903 is active in models of drug-resistant acute myeloid leukemia.
JCI insight - 3 Dec 2020
Jeon Jae Yoon, Buelow Daelynn R, Garrison Dominique A, Niu Mingshan, Eisenmann Eric D, Huang Kevin M, Zavorka Thomas Megan E, Weber Robert H, Whatcott Clifford J, Warner Steve L, Orwick Shelley J, Carmichael Bridget, Stahl Emily, Brinton Lindsey T, Lapalombella Rosa, Blachly James S, Hertlein Erin, Byrd John C, Bhatnagar Bhavana, Baker Sharyn D
Abstract excerpt
Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling, as well as cell cycle regulators in biochemical and cellular assays. In vitro and in vivo, TP-0903 was active in multiple models of drug-resistant FLT3 mutant AML,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.